{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:45:53Z","timestamp":1784727953640,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.adro.2020.06.001","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T10:16:35Z","timestamp":1592648195000},"page":"809-816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Radiation Therapy for Advanced-Stage Hodgkin Lymphoma"],"prefix":"10.1016","volume":"5","author":[{"given":"Natalie A.","family":"Lockney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2020.06.001_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.adro.2020.06.001_bib2","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2020.06.001_bib3","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib4","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin's lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2020.06.001_bib5","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: Survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.001_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib8","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2020.06.001_bib9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMc1609333","article-title":"Interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2020.06.001_bib11","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib12","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib13","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: Long-term results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib15","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/S0167-8140(19)30922-3","article-title":"OC-0502 Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: Results of FIL HD0801 trial","volume":"133","author":"Ricardi","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib16","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: Final results of the phase II part of the HD0801 Study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijrobp.2006.08.041","article-title":"Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma","volume":"67","author":"Aleman","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.001_bib18","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2020.06.001_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2020.06.001_bib20","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.adro.2020.06.001_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2020.06.001_bib22","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib24","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib27","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.001_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijrobp.2015.01.048","article-title":"Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group","volume":"92","author":"Kriz","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2020.06.001_bib29","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2020.06.001_bib30","first-page":"3035","article-title":"Effect of radiation therapy on survival in Hodgkin's lymphoma: A SEER data analysis","volume":"37","author":"Master","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.adro.2020.06.001_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003187.pub2","article-title":"Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk","author":"Franklin","year":"2005","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109420301482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109420301482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:37:19Z","timestamp":1762529839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109420301482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2452109420301482"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2020.06.001","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy for Advanced-Stage Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2020.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}